BDSI announces positive phase III clinical trial results

oval by FDA and that our development and commercialization activities continue as planned, we continue to believe that we will ultimately reach our annual peak sales projection of $250 million for the treatment of breakthrough cancer pain."

"On behalf of the Board of Directors, I want to congratulate our senior management and our entire BEMA Fentanyl team for achieving this pivotal milestone in the history of BDSI" said Frank E. ODonnell Jr., M.D., Chairman of the Board of BDSI. "Since the addition of Drs. Sirgo and Finn to our senior management team in 2004, BDSI has made great strides in its evolution from a drug delivery company into a specialty pharmaceutical company. In that time, under their dedicated, tireless and very able leadership, BDSI has carefully marshaled and focused its resources, faced and overcome many obstacles and stayed true to its pursuit of the capital and time efficient 505(b)(2) regulatory pathway. Our team has brought tangible value to our stockholders, and our board takes this time to state its appreciation and admiration of the efforts of our management team and all of our employees."

Dr. ODonnell continued, "We are hopeful that this demonstration of the effectiveness of BEMA Fentanyl augers very well for the potential application of the BEMA technology to other therapeutics that normally require parenteral administration. While it is true that work remains to be completed in the regulatory and commercial areas for BEMA Fentanyl, now that we have demonstrated the clinical value of this important delivery technology, we will seek to expand our pipeline of other clinically and economically valuable applications and partnerships."

Patients from the efficacy study were also eligible for entry in the long-term safety study with BEMA Fentanyl, which is still ongoing. The two studies together will form the foundation of BDSIs New Drug Application (NDA) scheduled for submission during the third quarter of 2007.

Contact: Bill Douglass
BioDelivery Sciences

Page: 1 2 3 4

Related biology news :

1. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
2. ESA announces 2007 award recipients
3. President Bush announces 2005 and 2006 Laureates of National Medals of Science and Technology
4. Conservation Leadership Program announces 2007 awardees
5. ACMG Foundation announces 2007-2008 Luminex/ACMGF award recipient
6. Revolutionary global environment fund announces $50M expansion
7. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
8. Cell Press announces new partnership with the American Society of Human Genetics
9. ChemGenex announces publication confirming activity of Ceflatonin in T315I-Positive CML
10. Minister Lunn announces $39.6M for next phase of mountain pine beetle response
11. BioMed Central announces new interdisciplinary Biofuels Journal

Post Your Comments:

(Date:7/18/2020)... ... July 16, 2020 , ... A study has been ... Medical Neoasis™ active noise control device to attenuate typical noises in a simulated ... attenuated the alarm sounds from patient monitors, ventilators and other bedside devices that ...
(Date:7/10/2020)... ... July 08, 2020 , ... ... Gene Therapy Regulation, An FDAnews Webinar, Wednesday, July 22, 2020 • 1:30 p.m.-3:00 ... but what is the most effective way to complete one? Will the study ...
(Date:7/4/2020)... ... July 03, 2020 , ... Aesthetics ... recognition and multiple awards for not only the products and treatments developed, but ... and Vivace® Microneedle RF. All the brands built by ABM have received several ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... ... eSource has long been touted as the solution to high data management and monitoring ... did not take off as quickly as people initially expected, and where eSource is ... data electronically for clinical trials and then repurposing it for downstream analysis, at a ...
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from ... Sr. Manager Regulatory Solutions, in a one hour live webinar on Thursday, ... body in China for drugs and medical devices. Specifically, for medical devices, the NMPA ...
(Date:7/18/2020)... , ... July 16, 2020 , ... ... to aid in the early detection and prevention of high-burden diseases, and Centric ... US-based hospitals and healthcare organizations to utilize existing data in order to identify ...
(Date:7/10/2020)... (PRWEB) , ... July 09, ... ... biotechnology company, announced today that Massachusetts Institute of Technology (MIT) has expanded ... broader license allows PathSensors to move into the point-of-care diagnostic market, focusing ...
Breaking Biology Technology:
Cached News: